NervGen Pharma appoints Bill Radvak as interim CEO

Sep. 23, 2022 3:37 AM ETNervGen Pharma Corp. (NGENF), NGEN:CABy: Meghavi Singh, SA News Editor
  • NervGen Pharma (OTCQX:NGENF) notifies that the board and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & CEO and a member of the board, effective immediately.
  • The board has appointed current Executive Chairman of the board Bill Radvak as interim CEO and current board member Dr. Adam Rogers as interim President.
  • Mr. Brennan will serve as a strategic advisor to management and the board during the transition period. The Board has initiated a search for a permanent CEO.
  • Mr. Radvak served as President of NervGen from January 2017 to June 2018.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.